For instance, vorinostat (Zolinza; Merck) [117], panobinostat (arydak; Novartis) [118], belinostat (Beleodap; Spectrum Pharmaceuticals) [119], and romidepsin (Istodax; Celgene) [120] have been approved for treating refractory multiple myeloma and cutaneous/peripheral T-cell lymphoma, where the first three drugs target HDAC1/2/3/6 and the last one inhibits HDAC1/2/3 [121]. Here, HDAC1 is linked to plasma cell myeloma.